论文部分内容阅读
许正博士,毕业于上海第二医科大学,在1991年旅居美国之前已开始涉及生物抗癌药物“亲细胞非均质分子脂质(简称CHML)的研究,并于1993年以中国学者个人身份在美国获得癌症药物专利商标和美国专利局颁发的专利证书。目前,许正等研究的新药已由美国高立食品药品有限公司批量生产。最近,译者收到许正博士寄来的一篇他们与美国国立癌症研究所合作发表在国际抗癌研究杂志(Anticancer Research27:1593-1600(2007))上的论文,现摘译如下。
Dr. Xu Zheng, a graduate of Shanghai Second Medical University, began his research on biological anti-cancer drugs ”CHML" before he resided in the United States in 1991. In 1993, he started his studies with Chinese scholars Identity in the United States to obtain a patent for cancer drugs patent and the United States Patent Office issued a patent certificate.At present, Xu Zheng and other research drugs have been produced by the United States Gaoli Food and Drug Co., Ltd. Recently, the translator received Dr Xu Zheng sent a The articles they published in collaboration with the National Cancer Institute in the journal Anticancer Research27: 1593-1600 (2007) are now reproduced below.